Accumulation of defective HIV-1 variants in a patient with slow disease progression

Current HIV Research

Volumn 9, Issue 1, 2011, Pages 17-22

  Paolucci, Stefania ^a   Gulminetti, Roberto ^a   Maserati, Renato ^a   Dossena, Luca ^a   Baldanti, Fausto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Defective variants; HIV 1; Pol mutations; RT stop codons; Slow progressor; Viral complementation; Viral replication

Indexed keywords

VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; LYMPHOCYTE; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPERNATANT; T LYMPHOCYTE; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; AMINO ACID SEQUENCE; CELLS, CULTURED; CODON, NONSENSE; DNA, VIRAL; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; VIRUS REPLICATION;

EID: 79951718066     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016211794582641     Document Type: Article

References (26)

1. Alexander L, Cuchura L, Simpson BJ, Andiman WA. Virologic and host characteristics of human immunodeficiency virus type 1- infected pediatric long term survivors. Pediatr Infect Dis J 2006; 25: 135-41.
2. Hassaïne G, Agostini I, Candotti D, et al. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology 2000; 276: 169-80.
3. Wang B, Dyer WB, Zaunders JJ, et al. Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection. Virology 2002; 304: 246-64.
4. Churchill MJ, Rhodes DI, Learmont JC, et al. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol 2006; 80: 1047-52.
5. Rangel HR, Garzaro D, Rodríguez AK, et al. Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries 2009; 3: 531-8.
6. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168-71.
7. Paolucci S, Foli A, Gulminetti R, et al. HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response. Curr HIV Res 2009; 7: 302-10.
8. Iwabu Y, Mizuta H, Kawase M, Kameoka M, Goto T, Ikuta K. Superinfection of defective human immunodeficiency virus type 1 with different subtypes of wild-type virus efficiently produces infectious variants with the initial viral phenotypes by complementation followed by recombination. Microbes Infect 2008; 10: 504-13.
9. Makinson A, Masquelier B, Taieb A, et al. Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART. AIDS 2006; 20: 1327-36.
10. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena NK. First demonstration of lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 2003; 312: 135-50.
11. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
12. Koizumi H, Hashimoto M, Fujiwara M, et al. Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J Virol 2010; 84: 5508-19.
13. Galiano L, Ding F, Veloro AM, Blackburn ME, Simmerling C, Fanucci GE. Drug pressure selected mutations in HIV-1 protease alter flap conformations. J Am Chem Soc 2009; 131: 430-1.
14. Deforche K, Cozzi-Lepri A, Theys K, et al. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 2008; 13: 399-407.
15. Paolucci S, Baldanti F, Maserati R, et al. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Res 2000; 45: 101-14.
16. Lori F, Hall L, Lusso P, et al. Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. J Virol 1992; 66: 5553-60.
17. Iwabu Y, Goto T, Tsuji S, et al. Superinfection of human immunodeficiency virus type 1 (HIV-1) to cell clone persistently infected with defective virus induces production of highly cytopathogenic HIV-1. Microbes Infect 2006; 8: 1773-82.
18. Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN. Viral complementation allows HIV-1 replication without integration. Retrovirology 2008; 5: 60.
19. Cara A, Guarnaccia F, Reitz MS, Gallo RC, Lori F. Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytes. Virology 1995; 208: 242-8.
20. Liao WH, Wang CT. Characterization of human immunodeficiency virus type 1 Pr160gag-pol mutants with truncations downstream of the protease domain. Virology 2004; 329: 180-8.
21. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pometantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323: 1304-7.
22. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
23. Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev 2002; 4: 224-32.
24. Sharma PL, Nettles JH, Feldman A, Rapp K, Schinazi RF. Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. Antiviral Res 2009; 83: 317-23.
25. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.
26. Soria A, Danise A, Galli L, et al. Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. J Clin Virol 2010; 47: 253-7.